M. Waldman

发表

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN

H. Handa, A. Klippel, R. Chopra, 2013, British journal of haematology.

Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.

J. Burke, J. Hainsworth, C. Sternberg, 2017, European urology.

Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell‐mediated cytotoxicity

M. Trotter, R. Chopra, P. Hagner, 2017, British journal of haematology.

Detection and Quantification of Cereblon Protein and mRNA in Multiple Myeloma Cell Lines and Primary CD138+multiple Myeloma Cells

H. Avet-Loiseau, R. Chopra, B. Cathers, 2012 .

Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy

A. Madan, R. Orlowski, H. Avet-Loiseau, 2013, Leukemia.

Autoimmune gene expression profiling of fingerstick whole blood in Chronic Fatigue Syndrome

Zheng Wang, Regis Perichon, A. R. Jacobs, 2022, Journal of Translational Medicine.

Interactome of Aiolos/Ikaros Reveals Combination Rationale of Cereblon Modulators with HDAC Inhibitors in DLBCL

P. Hagner, V. Chopra, Remco Loos, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.

M. Trotter, C. Fontanillo, A. Klippel, 2015, Blood.

Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity

R. Chopra, B. Cathers, P. Schafer, 2013, British journal of haematology.

Combination of Lenalidomide and Rituximab (R2) Targets Immune Dysfunction in FL By Activating T and NK Cells Ex Vivo and Is Differentiated from Chemotherapy

P. Hagner, Hsiling Chiu, M. Waldman, 2017 .

CC-122 Has Potent Anti-Lymphoma Activity through Destruction of the Aiolos and Ikaros Transcription Factors and Induction of Interferon Response Pathways

M. Trotter, C. Fontanillo, A. Klippel, 2014 .

CC-122 Exhibits Greater Preclinical Activity in Mantle Cell Lymphoma Than Lenalidomide through a Combination of Direct Cell-Autonomous and Increased Antibody Dependent Cell-Mediated Cytotoxicity

A. Klippel, P. Hagner, M. Pourdehnad, 2016 .

Discovery of a Novel Class of Orally Active Antifungal β-1,3-d-Glucan Synthase Inhibitors

R. J. Herr, P. Mann, S. Walker, 2011, Antimicrobial Agents and Chemotherapy.

CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL.

M. Trotter, C. Fontanillo, A. Klippel, 2015, Blood.

The predictive and prognostic value of peripheral blood antigen-specific memory B cells in phospholipase A2 receptor-associated membranous nephropathy

M. Waldman, M. Waldman, Q. Zhu, 2023, medRxiv.

Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.

J. Burke, J. Hainsworth, C. Sternberg, 2017, European Urology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.